Ardizol (furazolidone, oral): Uses, Dosage & Side Effects

What it's for (Indications)

Furazolidone, an antimicrobial and antiprotozoal agent, is primarily indicated for the treatment of specific diarrheal infections caused by susceptible bacterial and protozoal organisms.
Historically, its main applications have included bacterial enteritis caused by species such as *Escherichia coli*, *Staphylococcus aureus*, *Salmonella*, and *Shigella*.
Furthermore, it has been widely used in the management of giardiasis, an intestinal infection caused by the protozoan *Giardia lamblia* (also known as *Giardia intestinalis*).
In some regions, it has also been employed in the treatment of cholera due to susceptible *Vibrio cholerae* strains.
The use of furazolidone has become less common in many areas due to increasing antimicrobial resistance and the availability of alternative therapeutic agents with more favorable safety profiles.
However, it remains a valuable option in specific clinical scenarios where resistance to other agents is confirmed or when other treatments are contraindicated, providing a targeted approach against specific pathogens causing gastrointestinal distress.

Dosage Information

Type	Guideline
Standard	The dosage of oral furazolidone must be carefully determined by a healthcare professional based on the patient's age, weight, the specific infection being treated, and the severity of the condition. For adults and children over 12 years suffering from bacterial enteritis or giardiasis, a common regimen involves 100 mg administered four times daily (every 6 hours) for a duration of 5 to 7 days. For children aged 1 month to 12 years, the dosage is typically calculated based on body weight, often around 1.25 mg per kilogram of body weight, given four times daily for 7 to 10 days for giardiasis, or 5 to 7 days for bacterial enteritis, not exceeding the adult dose. It is crucial to administer the medication consistently for the entire prescribed duration, even if symptoms improve, to ensure complete eradication of the pathogen and prevent the development of resistance. The medication should be taken with food to minimize gastrointestinal upset. Dosing adjustments may be necessary in patients with renal impairment, though specific guidelines for such adjustments are not always well-defined and require careful clinical judgment and monitoring of renal function. Adherence to the prescribed regimen is paramount for therapeutic success.

Type

Guideline

Standard

The dosage of oral furazolidone must be carefully determined by a healthcare professional based on the patient's age, weight, the specific infection being treated, and the severity of the condition. For **adults and children over 12 years** suffering from bacterial enteritis or giardiasis, a common regimen involves 100 mg administered four times daily (every 6 hours) for a duration of 5 to 7 days. For **children aged 1 month to 12 years**, the dosage is typically calculated based on body weight, often around 1.25 mg per kilogram of body weight, given four times daily for 7 to 10 days for giardiasis, or 5 to 7 days for bacterial enteritis, not exceeding the adult dose. It is crucial to administer the medication consistently for the entire prescribed duration, even if symptoms improve, to ensure complete eradication of the pathogen and prevent the development of resistance. The medication should be taken with food to minimize gastrointestinal upset. Dosing adjustments may be necessary in patients with renal impairment, though specific guidelines for such adjustments are not always well-defined and require careful clinical judgment and monitoring of renal function. Adherence to the prescribed regimen is paramount for therapeutic success.

Safety & Warnings

Common Side Effects

Like all medications, oral furazolidone can cause adverse reactions, though not everyone experiences them.
Common side effects often involve the gastrointestinal system and include nausea, vomiting, abdominal pain, and diarrhea.
Some patients may also experience headache, dizziness, or a general feeling of malaise.
A less common but noticeable side effect is the darkening of urine, which is harmless and related to the drug's metabolism and does not indicate a serious issue.
More serious, albeit rare, side effects warrant immediate medical attention.
These can include hypersensitivity reactions such as rash, urticaria, angioedema, and fever.
Hematologic effects like hemolytic anemia, particularly in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, can occur and may be severe.
Neurological disturbances, such as peripheral neuropathy (characterized by numbness, tingling, or weakness in the extremities), have been reported, especially with prolonged use or in patients with renal impairment.
In some cases, a disulfiram-like reaction can occur if alcohol is consumed during treatment, leading to flushing, headache, nausea, and vomiting, necessitating strict avoidance of alcohol.

Serious Warnings

Black Box Warning: None
Furazolidone carries several significant warnings and precautions that necessitate careful consideration before and during its administration.
It is **contraindicated in infants under one month of age** due to the potential for hemolytic anemia and the immature enzyme systems in neonates, which render them more susceptible to adverse effects.
Patients with known **glucose-6-phosphate dehydrogenase (G6PD) deficiency** are at a high risk of developing severe hemolytic anemia during treatment, and furazolidone should be strictly avoided in these individuals.
A critical interaction concern arises from its **monoamine oxidase (MAO) inhibitory activity**.
Concomitant use with other MAO inhibitors or consumption of tyramine-rich foods (e.
g.
, aged cheeses, cured meats, red wine, fava beans, yeast extracts) can precipitate a life-threatening hypertensive crisis, characterized by severe headache, palpitations, sweating, and dangerously elevated blood pressure; patients must be educated extensively about these dietary and drug interactions.
A **disulfiram-like reaction** can occur if alcohol is consumed during therapy and for several days after discontinuation, leading to flushing, headache, nausea, and vomiting; therefore, alcohol consumption must be strictly avoided.
**Peripheral neuropathy** has been reported, particularly with prolonged high-dose therapy or in patients with pre-existing renal impairment, manifesting as numbness, tingling, or weakness in the extremities; treatment should be discontinued immediately if these symptoms arise to prevent irreversible nerve damage.
There are also **carcinogenicity and mutagenicity concerns** observed in animal studies; however, the relevance to human use, especially for short-term therapeutic regimens, is debated, but clinicians should be aware of these findings.
Caution is advised in patients with severe renal impairment, and hepatic function should be monitored in those with pre-existing liver disease due to potential for drug accumulation and toxicity.

How it Works (Mechanism of Action)

Furazolidone exerts its antimicrobial and antiprotozoal effects through a multifaceted mechanism that targets essential cellular processes within susceptible microorganisms. As a nitrofuran derivative, its action relies on metabolic reduction within the microbial cell. Once inside the bacterial or protozoal cell, furazolidone is reduced by microbial nitroreductases to highly reactive intermediates. These reactive metabolites then covalently bind to and damage critical macromolecules, including deoxyribonucleic acid (DNA), leading to strand breaks and inhibition of DNA replication, transcription, and repair processes. This direct DNA damage is largely responsible for its potent bactericidal and protozoacidal properties. Furthermore, these reactive intermediates interfere with several key enzyme systems vital for microbial metabolism. Specifically, furazolidone is known to inhibit certain bacterial enzyme systems, including components of the tricarboxylic acid cycle, pyruvate metabolism, and monoamine oxidase (MAO). The inhibition of MAO is particularly relevant for its systemic drug interactions, though its contribution to direct antimicrobial action is less central. This broad disruption of cellular integrity and metabolic pathways ultimately leads to the irreversible impairment of vital microbial functions and the death of the microorganism. Furazolidone exhibits a broad spectrum of activity against various Gram-positive and Gram-negative bacteria, as well as protozoa like *Giardia lamblia* and *Entamoeba histolytica*.